Compare AM & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | AM | ABVX |
|---|---|---|
| Founded | 2013 | 2013 |
| Country | United States | France |
| Employees | N/A | 67 |
| Industry | Natural Gas Distribution | |
| Sector | Utilities | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2B | 10.5B |
| IPO Year | 2017 | N/A |
| Metric | AM | ABVX |
|---|---|---|
| Price | $22.57 | $114.42 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 12 |
| Target Price | $21.33 | ★ $128.42 |
| AVG Volume (30 Days) | ★ 3.1M | 733.0K |
| Earning Date | 05-14-2026 | 01-01-0001 |
| Dividend Yield | ★ 3.92% | N/A |
| EPS Growth | ★ 3.61 | N/A |
| EPS | ★ 0.86 | N/A |
| Revenue | ★ $1,188,426,000.00 | N/A |
| Revenue This Year | $3.96 | N/A |
| Revenue Next Year | $6.26 | $0.22 |
| P/E Ratio | $26.62 | ★ N/A |
| Revenue Growth | ★ 7.43 | N/A |
| 52 Week Low | $15.08 | $4.77 |
| 52 Week High | $23.10 | $148.83 |
| Indicator | AM | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 67.88 | 45.01 |
| Support Level | $17.20 | $106.37 |
| Resistance Level | N/A | $131.27 |
| Average True Range (ATR) | 0.49 | 4.85 |
| MACD | -0.04 | -1.39 |
| Stochastic Oscillator | 76.75 | 31.26 |
Antero Midstream Corp is a midstream company that owns, operates, and develops midstream energy assets that service Antero Resources' production and completion activity in the Appalachian Basin, located in West Virginia and Ohio. The company has two operating segments: the Gathering and Processing segment, which includes a network of gathering pipelines and compressor stations that collect and process production from Antero Resources wells in West Virginia and Ohio, and the Water Handling segment, which includes two independent systems that deliver water from sources including the Ohio River, local reservoirs, and several regional waterways. The company derives a majority of its revenue from the Gathering and Processing segment.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.